Pharmala Biotech Holdings (MDMA) investor relations material

Commercial progress and market opportunity

• Achieved commercial sales of MDMA for clinical use in Canada and Australia, with a 70% PTSD remission rate in three months.

• Holds first-mover advantage in all current markets due to regulatory barriers and early entry.

• Expanding distribution to New Zealand, Europe (Netherlands, Switzerland, Czech Republic), and maintains a strong client base including major universities and institutions.

• Medibank in Australia now reimburses MDMA therapy, reducing long-term costs for insurers.

• Listed on OTCQB and Canadian Securities Exchange, recognized as Canada's top growth stock in 2023.

Product development and innovation

• Manufactures generic MDMA (LaNeo MDMA) and develops novel analogs with improved safety profiles.

• Utilizes AI-driven QSAR models to design and patent new molecules targeting CNS and psychiatric disorders.

• ALA-002, a safer MDMA analog, is in phase two trials for social anxiety; APA-01 targets neurological recovery and brain injury.

• New analogs show reduced cardiac toxicity and improved side effect profiles in preclinical studies.

• Collaborates with leading research institutions for data sharing and efficient clinical development.

Clinical protocols and therapeutic approach

• MDMA-assisted therapy involves three in-clinic sessions, with no take-home medication; the drug enhances therapy effectiveness.

• Follow-up at 6, 9, and 12 months confirms sustained remission using standard psychiatric scales.

• Focus remains on anxiety and fear disorders, with ongoing trials for schizophrenia and CNS disorders.

• Therapy protocol ensures minimal risk of diversion or recreational misuse.